CMMB Stock Price | Chemomab Therapeutics Ltd DRC P/E, Revenue, EPS, & Forecasts

Chemomab Therapeutics Ltd DRC • CMMB

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Chemomab Therapeutics Ltd DRC

Ticker

CMMB

Trading on

NASDAQ

ISIN

US16385C1045

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Adi Mor George Ph.D.

Headquarters

Building 7, Tel Aviv, undefined, Israel, 6158002

Employees

Website

chemomab.com

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Metrics

BasicAdvanced

Market cap

$27.2M

P/E ratio

EPS

-$0.81

Dividend Yield

0.00%

Beta

0.49

Forward P/E ratio

EBIDTA

$-14.7M

Ex dividend date

Price & volume

Market cap

$27.2M

Average daily volume

0.8M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

Price to book

1.88

Earnings

EPS

-$0.81

EPS estimate (current quarter)

-$0.01

EPS estimate (next quarter)

-$0.01

EBITDA

$-14.7M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

0.49

52-week High

$2.55

52-week Low

$0.58

50-day moving average

$1.83

200-day moving average

$1.54

Short ratio

0.51

Short %

2.08%

Management effectiveness

ROE (TTM)

91.34%

ROA (TTM)

47.10%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

18.9M

Float

236M

Insiders %

15.91%

Institutions %

25.92%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 3 analysts.

Average price target

$9.00

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.27

-$0.02

1,227.00%

Q4 • 23Beat

-$0.28

-$0.03

817.67%

Q1 • 24Beat

-$0.26

-$0.01

2,500.00%

Q2 • 24Beat

-$0.01

Q3 • 24Beat

-$0.01

20.00%

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-3.6M

∞%

Q2 • 24

$0M

$-3.5M

∞%

Q3 • 24

NaN%

4.08%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$14.5M

$4.6M

31.35%

Q2 • 24

$20.9M

$4.6M

21.91%

Q3 • 24

43.68%

0.44%

30.10%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

Q2 • 24

Q3 • 24

NaN%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Chemomab Therapeutics Ltd DRC share?

Chemomab Therapeutics Ltd DRC shares are currently traded for undefined per share.

How many shares does Chemomab Therapeutics Ltd DRC have?

Chemomab Therapeutics Ltd DRC currently has 18.9M shares.

Does Chemomab Therapeutics Ltd DRC pay dividends?

No, Chemomab Therapeutics Ltd DRC doesn't pay dividends.

What is Chemomab Therapeutics Ltd DRC 52 week high?

Chemomab Therapeutics Ltd DRC 52 week high is $2.55.

What is Chemomab Therapeutics Ltd DRC 52 week low?

Chemomab Therapeutics Ltd DRC 52 week low is $0.58.

What is the 200-day moving average of Chemomab Therapeutics Ltd DRC?

Chemomab Therapeutics Ltd DRC 200-day moving average is $1.54.

Who is Chemomab Therapeutics Ltd DRC CEO?

The CEO of Chemomab Therapeutics Ltd DRC is Dr. Adi Mor George Ph.D..

How many employees Chemomab Therapeutics Ltd DRC has?

Chemomab Therapeutics Ltd DRC has 0 employees.

What is the market cap of Chemomab Therapeutics Ltd DRC?

The market cap of Chemomab Therapeutics Ltd DRC is $27.2M.

What is the P/E of Chemomab Therapeutics Ltd DRC?

The current P/E of Chemomab Therapeutics Ltd DRC is null.

What is the EPS of Chemomab Therapeutics Ltd DRC?

The EPS of Chemomab Therapeutics Ltd DRC is -$0.81.

What is the PEG Ratio of Chemomab Therapeutics Ltd DRC?

The PEG Ratio of Chemomab Therapeutics Ltd DRC is null.

What do analysts say about Chemomab Therapeutics Ltd DRC?

According to the analysts Chemomab Therapeutics Ltd DRC is considered a buy.